Table 1 Baseline demographic at initial diagnosis and at first disease relapse or progression
At diagnosis (N = 404) | At first relapse or progression (N = 222) | |
|---|---|---|
Characteristics | Number (%) | Number (%) |
Age: median (range) | 64 (28–90) | 69 (37–91) |
≥65 | 189 (47%) | 145 (65%) |
Sex | ||
Female | 98 (24%) | 45 (20%) |
Male | 306 (76%) | 177 (80%) |
Stage at initial diagnosis | – | |
Incomplete staging | 13 (3%) | – |
I | 17 (4%) | – |
II | 15 (4%) | – |
III | 26 (6%) | – |
IV | 333 (82%) | – |
Status after first-line treatment | – | |
Early failure | – | 70 (32%) |
Late failure | – | 152 (68%) |
ECOG | ||
0 | 256 (64%) | 78 (37%) |
1 | 109 (27%) | 103 (49%) |
≥2 | 33 (8%) | 31 (15%) |
Missing | 6 | 10 |
LDH/ULN ratio | ||
≥1 | 130 (37%) | 64 (33%) |
<1 | 219 (63%) | 129 (67%) |
Missing | 55 | 29 |
WBC, ×109/L | ||
Missing | 37 | 20 |
Assessable | 367 | 202 |
median (range) | 7.2 (2.5–483.6) | 6.2 (2.0–208.5) |
MIPI score | ||
Median (range) | 5.89 (3.59–8.85) | 5.91 (3.25–8.42) |
Low risk | 124 (36%) | 66 (35%) |
Intermediate risk | 113 (33%) | 56 (30%) |
High risk | 110 (32%) | 67 (35%) |
Missing | 57 | 33 |
Ki-67a | ||
<10% | 26 (11%) | 5 (5%) |
10% to <30% | 99 (43%) | 26 (27%) |
≥30% | 105 (46%) | 64 (67%) |
Missing | 174 | 127 |
Histology | ||
Blastoid/pleomorphic | 32 (8%) | 39 (27%) |
Nonblastoid/pleomorphic | 372 (92%) | 108 (73%) |
Missing | 0 | 75 |
